evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4 questions · 4 findings · 1 reviews · All outcomes

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 4 · 100%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Interferon-alpha 1000 IU lozenges (topical) vs Interferon-alpha 2000 IU lozenges (topical)

Total ulcer burden · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    Interferon-alpha dose comparison
    Kilic 2009 (interferon-alpha 1000 IU vs 2000 IU lozenges, 84 patients): the data presented did not allow analysis; authors reported no statistically significant difference in total ulcer burden between the two doses.
    1 study · 84 participants
    GRADE not reported

Interferon-alpha (topical lozenges) vs placebo

Total number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Interferon-alpha (topical; hydrogel or lozenges) showed no clear difference in total number of oral ulcers compared with placebo; GRADE not reported.

1 finding from 1 review

Interferon-alpha (topical lozenges) vs placebo

Total ulcer burden · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    Kilic 2009 (interferon-alpha lozenges 1000 IU or 2000 IU vs placebo, 84 patients; high risk of selective reporting): the data presented did not allow analysis; authors reported no statistically significant difference…
    1 study · 84 participants
    GRADE not reported